CVA Family Office LLC Has $96,000 Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

CVA Family Office LLC trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 11.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,406 shares of the biopharmaceutical company’s stock after selling 175 shares during the period. CVA Family Office LLC’s holdings in Gilead Sciences were worth $96,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Norges Bank purchased a new position in Gilead Sciences in the fourth quarter valued at about $1,301,624,000. The Manufacturers Life Insurance Company raised its position in Gilead Sciences by 78.8% during the fourth quarter. The Manufacturers Life Insurance Company now owns 7,632,000 shares of the biopharmaceutical company’s stock valued at $618,268,000 after acquiring an additional 3,362,505 shares in the last quarter. Vanguard Group Inc. lifted its stake in Gilead Sciences by 2.6% in the first quarter. Vanguard Group Inc. now owns 114,732,575 shares of the biopharmaceutical company’s stock valued at $8,404,161,000 after acquiring an additional 2,910,147 shares during the last quarter. Wellington Management Group LLP grew its position in Gilead Sciences by 14.4% in the fourth quarter. Wellington Management Group LLP now owns 18,630,134 shares of the biopharmaceutical company’s stock worth $1,509,227,000 after acquiring an additional 2,350,550 shares in the last quarter. Finally, Swedbank AB acquired a new position in shares of Gilead Sciences during the 1st quarter worth $134,489,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $68.63, for a total transaction of $137,260.00. Following the sale, the insider now directly owns 96,380 shares in the company, valued at approximately $6,614,559.40. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on GILD. Royal Bank of Canada reiterated a “sector perform” rating and issued a $74.00 price objective on shares of Gilead Sciences in a report on Monday, July 1st. Morgan Stanley dropped their price target on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a research report on Friday, April 26th. Maxim Group lowered their target price on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Wednesday, May 1st. TD Cowen cut their target price on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research report on Friday, April 26th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $105.00 price target on shares of Gilead Sciences in a research report on Friday, April 19th. Twelve analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $81.81.

Gilead Sciences Stock Performance

GILD stock traded down $0.19 during midday trading on Wednesday, hitting $74.00. The stock had a trading volume of 4,214,395 shares, compared to its average volume of 7,380,039. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $87.86. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. The stock has a 50-day simple moving average of $69.18 and a 200 day simple moving average of $70.49. The firm has a market capitalization of $92.19 billion, a price-to-earnings ratio of 205.56, a P/E/G ratio of 3.37 and a beta of 0.18.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.